ARGENX SE (ARGX) is a reputable, global biopharmaceutical company focused on developing a world-class portfolio of differentiated antibody therapeutics for the treatment of severe autoimmune diseases and cancer. The company, incorporated in 2008, is located in the Netherlands and operates additional offices in Belgium and the United States.
One of the company's well-renowned products, Efgartigimod, is an innovative drug in the clinic for the treatment of neuromuscular and haematological indications. The company prides itself in its industry-leading SIMPLE Antibody™ platform, which descends from the powerful llama immune system. Using this platform, ARGENX SE aims to move its discovery programs into the clinic, such as ARGX-115 which is a first-in-class immunotherapy targeting GARP, a novel immune checkpoint.
ARGENX SE adopts a collaborative model in its operations, partnering with renowned global industry players in a bid to enhance its innovative efforts. To date, the company has struck partnerships with companies like Johnson and Johnson, Burrill, and AbbVie, through which they have managed to make significant advancements in their research and development efforts.
The company is powered by a team of biotech enthusiasts, who bring their worldwide experience and passion together to create breakthrough drugs that transform the lives of patients. With a market capitalization of over €8 Billion, it is evident that ARGENX SE’s operations are well recognized in the biotechnology market. The company's shares are listed in the Nasdaq Global Select Market and the Euronext Brussels stock exchange, providing investors with liquid access to participate in their revolutionary research activities.
As the company advances, it continues to live by its motto “crisp thinking, clear results” as it seeks innovative solutions to curb severe autoimmune diseases and cancers. The combination of a distinctive research platform, a pipeline of promising novel therapies, and strategic partnerships place ARGENX SE at the forefront of antibody biotechnology, assuring its global prominence and profitability in the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Two healthcare companies, Argenx Se (ARGX) and Boston Scientific (BSX), have received bullish sentiments from analysts. Stifel Nicolaus maintained a Buy rating on Argenx Se with a $1200.00 price target, while Oppenheimer also reiterated a Buy rating. Similarly, Stifel Nicolaus maintained a Buy rating on Boston Scientific with a $55.00 price target, with Piper Sandler also confirming a Buy rating.
argenx reported strong Q3 2026 financial results with product net sales of $1.7 billion, a 54% year-over-year increase, driven by VYVGART's performance in MG and CIDP. The company is expanding VYVGART's reach into rheumatology with upcoming sBLA filings and aims for 10 molecules in clinical development by year-end, supporting its Vision 2030 growth strategy. Operating expenses increased due to the FORTE acquisition, but revenue growth continued to outpace expenses, maintaining strong operating margins.
Analysts are showing bullish sentiment towards healthcare stocks Argenx Se (ARGX) and Neurocrine (NBIX). UBS analyst Xian Deng maintained a Buy rating on Argenx Se with a $1400 price target, while Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Neurocrine with a $214 price target. Both stocks currently hold a Strong Buy consensus rating from analysts, indicating significant upside potential.
Wells Fargo analyst Derek Archila maintained a Buy rating on Argenx Se (ARGX) with a price target of $1,355.00. Argenx Se has a Strong Buy analyst consensus rating with an average price target of $1,179.42, and the company reported significantly increased quarterly revenue and net profit compared to the previous year. This news comes despite recent challenges, including a study failure in Sjogren's disease and discontinuation of another study.
argenx (NASDAQ: ARGX) has significantly outperformed the market over the last five years, achieving an average annual return of 22.71%. An initial investment of $100 in ARGX five years ago would now be worth $279.28. The article highlights the substantial impact of compounded returns on investment growth over time.
argenx announced that its FB102 antibody met its primary endpoint in a Phase 2 celiac study, demonstrating statistically significant improvement over placebo in a biopsy-based measure after a gluten challenge. The company plans to advance FB102 into Phase 3 development and will share detailed results at a future medical meeting. This positive readout follows argenx's recent acquisition of Forte Biosciences, which had previously reported an early positive celiac signal.
Argenx has stopped a late-stage study of its drug efgartigimod (commercialized as Vyvgart) for Sjögren's disease after an interim analysis showed it was unlikely to meet its primary endpoint. This news caused Argenx shares to fall 16%, wiping out €8.5 billion ($9.5 billion) from its market value, marking its biggest one-day drop in almost three years. Despite Vyvgart's success in treating other autoimmune diseases, Sjögren's disease remains an area with high unmet need and no approved treatments.